A cell-based vaccine composed of autologous lymphoblastoid B cells activated against Epstein-Barr virus (EBV) in vitro with potential immunoprotective activity. Upon prophylactic administration, this vaccine may stimulate specific cytotoxic T-lymphocyte (CTL) and antibody responses against EBV-transformed B cells, thereby preventing an EBV-induced post-transplantation lymphoproliferative disorder. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
